The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...

A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...

A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...

New therapy for Huntington’s disease ‘may slow progression’ - There are thought to be around 7,000 people living with ...

PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...

The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...